1. Mitotic progression following DNA damage enables pattern recognition within micronuclei.
- Author
-
Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, and Greenberg RA
- Subjects
- Animals, CTLA-4 Antigen antagonists & inhibitors, Cell Cycle Checkpoints, Cell Line, Tumor, DNA Breaks, Double-Stranded, Disease Models, Animal, Female, Humans, Inflammation pathology, Interferons metabolism, Melanoma, Experimental drug therapy, Melanoma, Experimental metabolism, Melanoma, Experimental pathology, Membrane Proteins metabolism, Mice, Mice, Inbred C57BL, Nucleotidyltransferases metabolism, DNA Damage, Inflammation metabolism, Micronuclei, Chromosome-Defective, Mitosis, Receptors, Pattern Recognition metabolism, Signal Transduction
- Abstract
Inflammatory gene expression following genotoxic cancer therapy is well documented, yet the events underlying its induction remain poorly understood. Inflammatory cytokines modify the tumour microenvironment by recruiting immune cells and are critical for both local and systemic (abscopal) tumour responses to radiotherapy. A poorly understood feature of these responses is the delayed onset (days), in contrast to the acute DNA-damage responses that occur in minutes to hours. Such dichotomous kinetics implicate additional rate-limiting steps that are essential for DNA-damage-induced inflammation. Here we show that cell cycle progression through mitosis following double-stranded DNA breaks leads to the formation of micronuclei, which precede activation of inflammatory signalling and are a repository for the pattern-recognition receptor cyclic GMP-AMP synthase (cGAS). Inhibiting progression through mitosis or loss of pattern recognition by stimulator of interferon genes (STING)-cGAS impaired interferon signalling. Moreover, STING loss prevented the regression of abscopal tumours in the context of ionizing radiation and immune checkpoint blockade in vivo. These findings implicate temporal modulation of the cell cycle as an important consideration in the context of therapeutic strategies that combine genotoxic agents with immune checkpoint blockade.
- Published
- 2017
- Full Text
- View/download PDF